

# Special Issue

## Antimalarial Drug Candidates

### Message from the Guest Editors

Despite extensive efforts to control and eliminate malaria, the disease continues to present a significant public health threat around the world. The emergence of *Plasmodium* resistance to current antimalarial medications, the absence of effective vaccines, and the limited availability of alternative chemotherapeutic options underscore the urgent need to identify and develop novel antimalarial drug candidates. This pressing issue requires immediate attention and has been a very attractive field for new research whose primary goal is the discovery of antimalarial drug candidates. This Special Issue aims to offer a comprehensive overview of the development of antimalarial drug candidates for treating malaria in preclinical, translational, and clinical settings. We invite authors to submit original research or review articles that analyze the mechanism of action, efficacy, safety, and/or pharmacokinetics of new antimalarial drug candidates in different transmission settings.

---

### Guest Editors

Dr. Djane Baia-da-Silva

Instituto Leônidas & Maria Deane, ILMD/FIOCRUZ Amazonia, Manaus, Brazil

Dr. Anna Caroline Campos Aguiar

Paulista School of Medicine (UNIFESP/EPM), Federal University of São Paulo, São Paulo, Brazil

---

### Deadline for manuscript submissions

closed (25 August 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8

CiteScore 7.7

Indexed in PubMed



[mdpi.com/si/218820](https://www.mdpi.com/si/218820)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://www.mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

an Open Access Journal  
by MDPI

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)

# About the Journal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

## Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

## Author Benefits

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

